Nasovac S4 is India’s first nasal vaccine against influenza. This innovative vaccine was developed by the Serum Institute of India and launched in collaboration with the Pune-based diagnostic company Mylab Discovery Solutions.
This vaccine is a live quadrivalent influenza vaccine, specifically designed to shield individuals from four different flu virus strains. It targets:
These strains are responsible for the seasonal epidemics of influenza, making Nasovac S4 an essential tool in flu prevention.
Nasovac S4 is recommended for individuals aged 2 years and older. It is intended to provide active immunization against influenza caused by the strains covered in the vaccine, and it is suggested that individuals receive this vaccination annually.
This nasal spray vaccine operates by initiating its action in the nasal passages. It effectively stimulates the immune system to produce antibodies that combat influenza infection. Unlike traditional needle-based injections, Nasovac S4 offers the dual benefits of systemic and local protection, effectively preventing viral adherence on the mucosal surfaces of the upper respiratory airways.
Influenza vaccines, including Nasovac S4, are not included in the government’s Universal Immunization Programme in India. Instead, they are available privately. Individuals interested in obtaining the influenza vaccination can do so independently. These vaccines play a vital role in halting the spread of the influenza virus and mitigating the risks of complications associated with the disease.
Kutos : AI Assistant!
